Beam Therapeutics upgraded to Outperform from Market Perform at Leerink [Yahoo! Finance]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Yahoo! Finance
The firm notes that prior to Tuesday's BEAM-101 data in sickle-cell disease, risk of a safety signal kept Leerink on the sidelines. Following disclosure of a patient death, shares opened down over 10%, but recovered over the day, as focus shifted to BEAM-301 data in alpha-1 antitrypsin deficiency, where the firm sees a far more attractive risk/reward. Leerink takes this opportunity to step back in positively after a period of uninspiring stock performance given strong product/market-fit for in vivo single-point mutation base editing in AATD, and potential to address both lung and liver manifestations. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now See today's best-performing stocks on TipRanks Read More on BEAM: Beam Therapeutics Reports Steady Progress in Q3 2024 Cathie Wood's ARK Investment buys 162.5K shares of Beam Therapeutics today Beam could see significant upside over next 6-12 months, says Wedbush B
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics to Participate in 2024 Jefferies London Healthcare ConferenceGlobeNewswire
- Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch [Seeking Alpha]Seeking Alpha
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.MarketBeat
- Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.MarketBeat
BEAM
Earnings
- 11/5/24 - Miss
BEAM
Sec Filings
- 11/12/24 - Form SC
- 11/8/24 - Form 4
- 11/8/24 - Form SC
- BEAM's page on the SEC website